<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC9616370</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC9616370.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">9616370</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">9616370</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36324717</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1016/j.cccb.2021.100013</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pii">S2666-2450(21)00010-6</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">100013</article-id></all-ids><extracted-table><table-id>utbl0001</table-id><table-label/><table-caption/><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="utbl0001" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td valign="top" colspan="1" rowspan="1"><bold>SVDs@target</bold> (Small vessel diseases in a mechanistic perspective: Targets for Intervention – Affected pathways and mechanistic exploitation for prevention of stroke and dementia) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.svds-at-target.eu" id="interref0001">www.svds-at-target.eu</ext-link>). The program is funded by Horizon 2020 and includes three clinical studies: ZOOM@SVDs (current paper), INVESTIGATE-SVDs, and TREAT-SVDs. This textbox provides a summary on INVESTIGATE-SVDs and TREAT-SVDs.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>INVESTIGATE-SVDs</bold> (Imaging NeuroVascular, Endothelial and STructural InteGrity in prepAration to TrEat Small Vessel Diseases.): PI Prof JM Wardlaw, Centre for Clinical Brain Sciences Edinburgh.</td></tr><tr><td valign="top" colspan="1" rowspan="1">INVESTIGATE-SVDs is a three-centre (Edinburgh, Maastricht, Munich) observational study in 45 patients with sporadic SVDs and in 30 patients with CADASIL. The main objective is to advance knowledge of SVD pathophysiology by assessing the relationship between blood brain barrier integrity, cerebrovascular reactivity to CO<sub>2</sub>, intracranial vascular and CSF pulsatility, blood pressure and its variability and clinical and structural features of SVD.</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>TREAT-SVDs</bold> (EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases): PI Prof M Dichgans, Institute for Stroke and Dementia Research, Ludwig-Maximilians-Universität, Munich</td></tr><tr><td valign="top" colspan="1" rowspan="1">TREAT-SVDs is a five-centre (Edinburgh, Maastricht, Munich, Oxford, Utrecht), randomized, open-label, crossover trial in 75 patients with sporadic SVDs and 30 patients with CADASIL. The primary objective is to test the hypothesis that the calcium channel blocker amlodipine has a beneficial effect on small vessel function in patients with symptomatic SVDs when compared to either the Angiotensin II type 1 receptor blocker losartan or the beta-blocker atenolol. The secondary objective is to test the hypothesis that losartan has a beneficial effect on small vessel function compared to atenolol.</td></tr></tbody></table></table-wrap></original-table><transformed-table><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td valign="top">SVDs@target (Small vessel diseases in a mechanistic perspective: Targets for Intervention – Affected pathways and mechanistic exploitation for prevention of stroke and dementia) (www.svds-at-target.eu). The program is funded by Horizon 2020 and includes three clinical studies: ZOOM@SVDs (current paper), INVESTIGATE-SVDs, and TREAT-SVDs. This textbox provides a summary on INVESTIGATE-SVDs and TREAT-SVDs.</td></tr><tr><td valign="top">INVESTIGATE-SVDs (Imaging NeuroVascular, Endothelial and STructural InteGrity in prepAration to TrEat Small Vessel Diseases.): PI Prof JM Wardlaw, Centre for Clinical Brain Sciences Edinburgh.</td></tr><tr><td valign="top">INVESTIGATE-SVDs is a three-centre (Edinburgh, Maastricht, Munich) observational study in 45 patients with sporadic SVDs and in 30 patients with CADASIL. The main objective is to advance knowledge of SVD pathophysiology by assessing the relationship between blood brain barrier integrity, cerebrovascular reactivity to CO2, intracranial vascular and CSF pulsatility, blood pressure and its variability and clinical and structural features of SVD.</td></tr><tr><td valign="top">TREAT-SVDs (EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases): PI Prof M Dichgans, Institute for Stroke and Dementia Research, Ludwig-Maximilians-Universität, Munich</td></tr><tr><td valign="top">TREAT-SVDs is a five-centre (Edinburgh, Maastricht, Munich, Oxford, Utrecht), randomized, open-label, crossover trial in 75 patients with sporadic SVDs and 30 patients with CADASIL. The primary objective is to test the hypothesis that the calcium channel blocker amlodipine has a beneficial effect on small vessel function in patients with symptomatic SVDs when compared to either the Angiotensin II type 1 receptor blocker losartan or the beta-blocker atenolol. The secondary objective is to test the hypothesis that losartan has a beneficial effect on small vessel function compared to atenolol.</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0001</table-id><table-label>Table 1</table-label><table-caption>Overview of data collection per visit.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Overview of data collection per visit.</p></caption><alt-text id="alt0003">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">Baseline visit 1<break/>Day 1</th><th valign="top" colspan="1" rowspan="1">Baseline visit 2<break/>Day 8–28</th><th valign="top" colspan="1" rowspan="1">Follow-up<break/>2 years</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Informed consent</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Clinical assessment</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1">Blood sampling</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Neuropsychological assessment</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1">7-day blood pressure monitoring</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">3T brain MRI</td><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">X</td></tr><tr><td valign="top" colspan="1" rowspan="1">7T brain MRI</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1">X</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Overview of data collection per visit.</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Baseline visit 1Day 1</th><th valign="top">Baseline visit 2Day 8–28</th><th valign="top">Follow-up2 years</th></tr></thead><tbody><tr><td valign="top">Informed consent</td><td valign="top">X</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Clinical assessment</td><td valign="top">X</td><td valign="top"/><td valign="top">X</td></tr><tr><td valign="top">Blood sampling</td><td valign="top">X</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Neuropsychological assessment</td><td valign="top">X</td><td valign="top"/><td valign="top">X</td></tr><tr><td valign="top">7-day blood pressure monitoring</td><td valign="top">X</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">3T brain MRI</td><td valign="top">X</td><td valign="top"/><td valign="top">X</td></tr><tr><td valign="top">7T brain MRI</td><td valign="top"/><td valign="top">X</td><td valign="top"/></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0002</table-id><table-label>Table 2</table-label><table-caption>Inclusion and exclusion criteria for patients with sporadic SVDs, CADASIL and healthy controls.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>Inclusion and exclusion criteria for patients with sporadic SVDs, CADASIL and healthy controls.</p></caption><alt-text id="alt0004">Table 2</alt-text><table frame="hsides" rules="groups"><tbody><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold>General selection criteria for all groups</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Inclusion criteria</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Exclusion criteria</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><list list-type="simple" id="celist0003"><list-item id="celistitem0009"><label>–</label><p id="para0052">Age 18 years or older</p></list-item><list-item id="celistitem0010"><label>–</label><p id="para0053">Capacity to give written informed consent</p></list-item><list-item id="celistitem0011"><label>–</label><p id="para0054">Independent in activities of daily living (Modified Rankin score ≤ 3)</p></list-item></list></td><td valign="top" colspan="1" rowspan="1"><list list-type="simple" id="celist0004"><list-item id="celistitem0012"><label>–</label><p id="para0055">Pregnant or breastfeeding women and women of childbearing age not taking contraception</p></list-item><list-item id="celistitem0013"><label>–</label><p id="para0056">Contraindication to MRI or unable to undergo MRI protocol due to physical condition</p></list-item><list-item id="celistitem0014"><label>–</label><p id="para0057">Other major neurological or psychiatric conditions affecting the brain and interfering with the study design (e.g. multiple sclerosis, Parkinson's disease)</p></list-item><list-item id="celistitem0015"><label>–</label><p id="para0058">Life expectancy &lt;2 years</p></list-item></list></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold>Additional selection criteria specific to patients with sporadic SVDs</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Inclusion criteria</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Exclusion criteria</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">History of a clinical lacunar stroke in the last 5 years with a corresponding small subcortical infarct visible on MRI or CT, compatible with the clinical syndrome<break/><underline>OR</underline><break/>Cognitive impairment defined as visiting a memory clinic with cognitive complaints and objective cognitive impairment (based on a validated cognitive measurement tool such as, but not limited to, CAMCOG) with confluent white matter hyperintensities on MRI (defined as Fazekas ≥ 2)</td><td valign="top" colspan="1" rowspan="1">- Evidence for a monogenic form of SVDs<break/>- In case of inclusion for clinical lacunar stroke:<break/>≥50% luminal stenosis in large arteries supplying the infarct area<break/>Major-risk for cardioembolic source of embolism (defined as permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumors, mitral stenosis, myocardial infarction in the last 4 weeks, left ventricular ejection fraction &lt; 30%, valvular vegetations, or infective endocarditis)<break/>Other specific causes of stroke (e.g. arteritis, dissection, vasospasm, drug misuse)</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold>Additional selection criteria specific to patients with CADASIL</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Inclusion criteria</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Exclusion criteria</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">A diagnosis of CADASIL established by molecular genetic testing of the <italic toggle="yes">NOTCH3</italic> gene (presence of an archetypical, cysteine-affecting mutation) or the presence of granular osmiophilic material in ultrastructural, electron microscopy analysis of skin biopsy. <italic toggle="yes">NB: thus both symptomatic and asymptomatic patients are included.</italic></td><td valign="top" colspan="1" rowspan="1">Not applicable</td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><bold>Additional selection criteria specific to controls</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Inclusion criteria</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Exclusion criteria</bold></td></tr><tr><td colspan="2" rowspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" rowspan="1">No additional inclusion criteria applicable</td><td valign="top" colspan="1" rowspan="1">- A history of stroke or of cognitive complaints for which the person has previously sought medical advice<break/>- So-called “silent” SVDs defined as confluent white matter hyperintensities (Fazekas ≥ 2) or lacunes on the 3T brain MRI scan on baseline visit 1</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Inclusion and exclusion criteria for patients with sporadic SVDs, CADASIL and healthy controls.</div>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><tbody><tr><td colspan="2" align="left" valign="top">General selection criteria for all groups</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">Inclusion criteria</td><td valign="top">Exclusion criteria</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">–Age 18 years or older–Capacity to give written informed consent–Independent in activities of daily living (Modified Rankin score ≤ 3)</td><td valign="top">–Pregnant or breastfeeding women and women of childbearing age not taking contraception–Contraindication to MRI or unable to undergo MRI protocol due to physical condition–Other major neurological or psychiatric conditions affecting the brain and interfering with the study design (e.g. multiple sclerosis, Parkinson's disease)–Life expectancy &lt;2 years</td></tr><tr><td colspan="2"/></tr><tr><td colspan="2" align="left" valign="top">Additional selection criteria specific to patients with sporadic SVDs</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">Inclusion criteria</td><td valign="top">Exclusion criteria</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">History of a clinical lacunar stroke in the last 5 years with a corresponding small subcortical infarct visible on MRI or CT, compatible with the clinical syndromeORCognitive impairment defined as visiting a memory clinic with cognitive complaints and objective cognitive impairment (based on a validated cognitive measurement tool such as, but not limited to, CAMCOG) with confluent white matter hyperintensities on MRI (defined as Fazekas ≥ 2)</td><td valign="top">- Evidence for a monogenic form of SVDs- In case of inclusion for clinical lacunar stroke:≥50% luminal stenosis in large arteries supplying the infarct areaMajor-risk for cardioembolic source of embolism (defined as permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumors, mitral stenosis, myocardial infarction in the last 4 weeks, left ventricular ejection fraction &lt; 30%, valvular vegetations, or infective endocarditis)Other specific causes of stroke (e.g. arteritis, dissection, vasospasm, drug misuse)</td></tr><tr><td colspan="2"/></tr><tr><td colspan="2" align="left" valign="top">Additional selection criteria specific to patients with CADASIL</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">Inclusion criteria</td><td valign="top">Exclusion criteria</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">A diagnosis of CADASIL established by molecular genetic testing of the NOTCH3 gene (presence of an archetypical, cysteine-affecting mutation) or the presence of granular osmiophilic material in ultrastructural, electron microscopy analysis of skin biopsy. NB: thus both symptomatic and asymptomatic patients are included.</td><td valign="top">Not applicable</td></tr><tr><td colspan="2"/></tr><tr><td colspan="2" align="left" valign="top">Additional selection criteria specific to controls</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">Inclusion criteria</td><td valign="top">Exclusion criteria</td></tr><tr><td colspan="2"/></tr><tr><td valign="top">No additional inclusion criteria applicable</td><td valign="top">- A history of stroke or of cognitive complaints for which the person has previously sought medical advice- So-called “silent” SVDs defined as confluent white matter hyperintensities (Fazekas ≥ 2) or lacunes on the 3T brain MRI scan on baseline visit 1</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0003</table-id><table-label>Table 3</table-label><table-caption>Neuropsychological tests and questionnaires in fixed order. MMSE= Mini-Mental State Examination, CES-D= Center for Epidemiological Studies Depression Scale.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0003" orientation="portrait"><label>Table 3</label><caption><p>Neuropsychological tests and questionnaires in fixed order. MMSE= Mini-Mental State Examination, CES-<italic toggle="yes">D</italic>= Center for Epidemiological Studies Depression Scale.</p></caption><alt-text id="alt0005">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Neuropsychological tests</th><th valign="top" colspan="1" rowspan="1">Cognitive function</th><th valign="top" colspan="1" rowspan="1">Cognitive domain</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Category fluency (animals, 60 s)</td><td valign="top" colspan="1" rowspan="1">Verbal fluency, semantic memory</td><td valign="top" colspan="1" rowspan="1">Executive function</td></tr><tr><td valign="top" colspan="1" rowspan="1">Boston naming test (short version)</td><td valign="top" colspan="1" rowspan="1">Word naming</td><td valign="top" colspan="1" rowspan="1">Language</td></tr><tr><td valign="top" colspan="1" rowspan="1">MMSE</td><td valign="top" colspan="1" rowspan="1">Cognitive screening</td><td valign="top" colspan="1" rowspan="1">–</td></tr><tr><td valign="top" colspan="1" rowspan="1">Word List Learning</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"> Immediate recall</td><td valign="top" colspan="1" rowspan="1">Episodic memory</td><td valign="top" colspan="1" rowspan="1">Memory</td></tr><tr><td valign="top" colspan="1" rowspan="1"> Delayed recall</td><td valign="top" colspan="1" rowspan="1">Episodic memory</td><td valign="top" colspan="1" rowspan="1">Memory</td></tr><tr><td valign="top" colspan="1" rowspan="1"> Delayed recognition</td><td valign="top" colspan="1" rowspan="1">Episodic memory</td><td valign="top" colspan="1" rowspan="1">Memory</td></tr><tr><td valign="top" colspan="1" rowspan="1">Constructional praxis</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"> Copy</td><td valign="top" colspan="1" rowspan="1">Visuoconstruction</td><td valign="top" colspan="1" rowspan="1">Visuoconstruction</td></tr><tr><td valign="top" colspan="1" rowspan="1"> Delayed recall</td><td valign="top" colspan="1" rowspan="1">Visuospatial memory, visuoconstruction</td><td valign="top" colspan="1" rowspan="1">Memory</td></tr><tr><td valign="top" colspan="1" rowspan="1">Trail making test</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"> Part A</td><td valign="top" colspan="1" rowspan="1">Attention and psychomotor speed</td><td valign="top" colspan="1" rowspan="1">Attention and processing speed</td></tr><tr><td valign="top" colspan="1" rowspan="1"> Part B</td><td valign="top" colspan="1" rowspan="1">Executive function</td><td valign="top" colspan="1" rowspan="1">Executive function</td></tr><tr><td valign="top" colspan="1" rowspan="1">Phonemic fluency (letter S, 60 s)</td><td valign="top" colspan="1" rowspan="1">Verbal fluency, executive function</td><td valign="top" colspan="1" rowspan="1">Executive function</td></tr><tr><td valign="top" colspan="1" rowspan="1">Digit span</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"> Forward</td><td valign="top" colspan="1" rowspan="1">Attention and information processing speed</td><td valign="top" colspan="1" rowspan="1">Attention and processing speed</td></tr><tr><td valign="top" colspan="1" rowspan="1"> Backward</td><td valign="top" colspan="1" rowspan="1">Working memory</td><td valign="top" colspan="1" rowspan="1">Executive function</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>Questionnaires</bold></td><td valign="top" colspan="1" rowspan="1"><bold>Scope</bold></td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">Clinical Dementia Rating scale</td><td valign="top" colspan="1" rowspan="1">Cognitive screening questionnaire</td><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1">CES-D questionnaire</td><td valign="top" colspan="1" rowspan="1">Depressive symptoms questionnaire</td><td valign="top" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Neuropsychological tests and questionnaires in fixed order. MMSE= Mini-Mental State Examination, CES-D= Center for Epidemiological Studies Depression Scale.</div>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Neuropsychological tests</th><th valign="top">Cognitive function</th><th valign="top">Cognitive domain</th></tr></thead><tbody><tr><td valign="top">Category fluency (animals, 60 s)</td><td valign="top">Verbal fluency, semantic memory</td><td valign="top">Executive function</td></tr><tr><td valign="top">Boston naming test (short version)</td><td valign="top">Word naming</td><td valign="top">Language</td></tr><tr><td valign="top">MMSE</td><td valign="top">Cognitive screening</td><td valign="top">–</td></tr><tr><td valign="top">Word List Learning</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Immediate recall</td><td valign="top">Episodic memory</td><td valign="top">Memory</td></tr><tr><td valign="top"> Delayed recall</td><td valign="top">Episodic memory</td><td valign="top">Memory</td></tr><tr><td valign="top"> Delayed recognition</td><td valign="top">Episodic memory</td><td valign="top">Memory</td></tr><tr><td valign="top">Constructional praxis</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Copy</td><td valign="top">Visuoconstruction</td><td valign="top">Visuoconstruction</td></tr><tr><td valign="top"> Delayed recall</td><td valign="top">Visuospatial memory, visuoconstruction</td><td valign="top">Memory</td></tr><tr><td valign="top">Trail making test</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Part A</td><td valign="top">Attention and psychomotor speed</td><td valign="top">Attention and processing speed</td></tr><tr><td valign="top"> Part B</td><td valign="top">Executive function</td><td valign="top">Executive function</td></tr><tr><td valign="top">Phonemic fluency (letter S, 60 s)</td><td valign="top">Verbal fluency, executive function</td><td valign="top">Executive function</td></tr><tr><td valign="top">Digit span</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top"> Forward</td><td valign="top">Attention and information processing speed</td><td valign="top">Attention and processing speed</td></tr><tr><td valign="top"> Backward</td><td valign="top">Working memory</td><td valign="top">Executive function</td></tr><tr><td valign="top">Questionnaires</td><td valign="top">Scope</td><td valign="top"/></tr><tr><td valign="top">Clinical Dementia Rating scale</td><td valign="top">Cognitive screening questionnaire</td><td valign="top"/></tr><tr><td valign="top">CES-D questionnaire</td><td valign="top">Depressive symptoms questionnaire</td><td valign="top"/></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0004</table-id><table-label>Table 4</table-label><table-caption>3T brain MRI protocol. GE= gradient echo; TSE= turbo spin echo; FLAIR= Fluid attenuated inversion recovery; DTI= diffusion tensor imaging; BOLD= Blood oxygenation level-dependent; rs-fMRI= resting state functional magnetic resonance imaging; Qflow = quantitative flow; (pC)ASL= (pseudoContinuous) Arterial spin labeling; SWI= susceptibility weighted imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0004" orientation="portrait"><label>Table 4</label><caption><p>3T brain MRI protocol. GE= gradient echo; TSE= turbo spin echo; FLAIR= Fluid attenuated inversion recovery; DTI= diffusion tensor imaging; BOLD= Blood oxygenation level-dependent; rs-fMRI= resting state functional magnetic resonance imaging; Qflow = quantitative flow; (pC)ASL= (pseudoContinuous) Arterial spin labeling; SWI= susceptibility weighted imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time.</p></caption><alt-text id="alt0006">Table 4:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">MR sequence</th><th valign="top" colspan="1" rowspan="1">Acquired resolution mm<sup>3</sup></th><th valign="top" colspan="1" rowspan="1">Time min:s</th><th valign="top" colspan="1" rowspan="1">Parameters</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Utrecht</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">T1-weighted GE</td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">05:39</td><td valign="top" colspan="1" rowspan="1">FOV 256 × 232 × 192 mm<sup>3</sup>; TR 8 ms; TI 955 ms; shot interval 2500 ms; flip angle 7°</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2-weighted TSE</td><td valign="top" colspan="1" rowspan="1">0.7 × 0.7 × 0.7</td><td valign="top" colspan="1" rowspan="1">07:37</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 190 mm<sup>3</sup>; TR 2500 ms; TE 298 ms</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2*-weighted GE</td><td valign="top" colspan="1" rowspan="1">0.8 × 0.8 × 0.8</td><td valign="top" colspan="1" rowspan="1">02:22</td><td valign="top" colspan="1" rowspan="1">FOV 230 × 192 × 144 mm<sup>3</sup>; TR 69 ms; TE 29 ms; flip angle 23°</td></tr><tr><td valign="top" colspan="1" rowspan="1">FLAIR</td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">06:15</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 180 mm<sup>3</sup>; TR 5000 ms; TE 253 ms; TI 1700 ms</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diffusion MRI</td><td valign="top" colspan="1" rowspan="1">2.5 × 2.5 × 2.5</td><td valign="top" colspan="1" rowspan="1">06:49</td><td valign="top" colspan="1" rowspan="1">FOV 220 × 220 × 120 mm<sup>3</sup>; TR 8185 ms; TE 73 ms; b-values 0 and 1200 s/mm<sup>2</sup>; directions 45</td></tr><tr><td valign="top" colspan="1" rowspan="1">BOLD rs-fMRI</td><td valign="top" colspan="1" rowspan="1">2.9 × 2.9 × 3.5</td><td valign="top" colspan="1" rowspan="1">05:00</td><td valign="top" colspan="1" rowspan="1">FOV 200 × 235 × 146 mm<sup>3</sup>; TR 2500 ms; 3 echos at TE 9.1, 25.3, and 41.4 ms <xref rid="bib0045" ref-type="bibr">[45]</xref></td></tr><tr><td valign="top" colspan="1" rowspan="1">Qflow</td><td valign="top" colspan="1" rowspan="1">1.2 × 1.2 × 2.0</td><td valign="top" colspan="1" rowspan="1">00:19</td><td valign="top" colspan="1" rowspan="1">FOV 150 × 103 mm<sup>2</sup>; TR 14 ms; TE 3.7 ms; flip angle 25°; Venc 100 cm/s</td></tr><tr><td valign="top" colspan="1" rowspan="1">ASL</td><td valign="top" colspan="1" rowspan="1">3.0 × 3.1 × 7.0</td><td valign="top" colspan="1" rowspan="1">06:00</td><td valign="top" colspan="1" rowspan="1">FOV 240 × 240 × 133 mm<sup>3</sup>; pCASL; label duration 1800 ms; postlabeling delay 1800 ms; 40 dynamics</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Munich</bold></td></tr><tr><td valign="top" colspan="1" rowspan="1">T1-weighted GE</td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">05:08</td><td valign="top" colspan="1" rowspan="1">FOV 256 × 256 × 192 mm<sup>3</sup>; TR 2500 ms; TE 4.37 ms; TI 1100 ms; flip angle 7°</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2-weighted TSE</td><td valign="top" colspan="1" rowspan="1">0.9 × 0.9 × 0.9</td><td valign="top" colspan="1" rowspan="1">03:42</td><td valign="top" colspan="1" rowspan="1">FOV 263 × 350 × 350 mm<sup>3</sup>; TR 3200 ms; TE 408 ms</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2*-weighted GE</td><td valign="top" colspan="1" rowspan="1">0.9 × 0.9 × 2.0</td><td valign="top" colspan="1" rowspan="1">05:56</td><td valign="top" colspan="1" rowspan="1">FOV 230 × 160 × 187 mm<sup>3</sup>; TR 35 ms; TE 5–30 ms; flip angle 15°</td></tr><tr><td valign="top" colspan="1" rowspan="1">SWI</td><td valign="top" colspan="1" rowspan="1">0.6 × 0.6 × 3.0</td><td valign="top" colspan="1" rowspan="1">04:02</td><td valign="top" colspan="1" rowspan="1">FOV 240 × 156 × 195 mm<sup>3</sup>; TR 28 ms; TE 20 ms; flip angle 9°</td></tr><tr><td valign="top" colspan="1" rowspan="1">FLAIR</td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">06:27</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 176 mm<sup>3</sup>; TR 5000 ms; TE 398 ms; TI 1800 ms</td></tr><tr><td valign="top" colspan="1" rowspan="1">Diffusion MRI</td><td valign="top" colspan="1" rowspan="1">2.0 × 2.0 × 2.0</td><td valign="top" colspan="1" rowspan="1">07:47</td><td valign="top" colspan="1" rowspan="1">FOV 240 × 150 × 240 mm<sup>3</sup>; TR 3800 ms; TE 104.8 ms; b-values 0, 1000 and 2000 s/mm<sup>2</sup>; 90 diffusion directions (30 for <italic toggle="yes">b</italic> = 1000 s/mm2 and 60 for <italic toggle="yes">b</italic> = 2000 s/mm2)</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">3T brain MRI protocol. GE= gradient echo; TSE= turbo spin echo; FLAIR= Fluid attenuated inversion recovery; DTI= diffusion tensor imaging; BOLD= Blood oxygenation level-dependent; rs-fMRI= resting state functional magnetic resonance imaging; Qflow = quantitative flow; (pC)ASL= (pseudoContinuous) Arterial spin labeling; SWI= susceptibility weighted imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time.</div>Table 4:<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">MR sequence</th><th valign="top">Acquired resolution mm3</th><th valign="top">Time min:s</th><th valign="top">Parameters</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top">Utrecht</td></tr><tr><td valign="top">T1-weighted GE</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">05:39</td><td valign="top">FOV 256 × 232 × 192 mm3; TR 8 ms; TI 955 ms; shot interval 2500 ms; flip angle 7°</td></tr><tr><td valign="top">T2-weighted TSE</td><td valign="top">0.7 × 0.7 × 0.7</td><td valign="top">07:37</td><td valign="top">FOV 250 × 250 × 190 mm3; TR 2500 ms; TE 298 ms</td></tr><tr><td valign="top">T2*-weighted GE</td><td valign="top">0.8 × 0.8 × 0.8</td><td valign="top">02:22</td><td valign="top">FOV 230 × 192 × 144 mm3; TR 69 ms; TE 29 ms; flip angle 23°</td></tr><tr><td valign="top">FLAIR</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">06:15</td><td valign="top">FOV 250 × 250 × 180 mm3; TR 5000 ms; TE 253 ms; TI 1700 ms</td></tr><tr><td valign="top">Diffusion MRI</td><td valign="top">2.5 × 2.5 × 2.5</td><td valign="top">06:49</td><td valign="top">FOV 220 × 220 × 120 mm3; TR 8185 ms; TE 73 ms; b-values 0 and 1200 s/mm2; directions 45</td></tr><tr><td valign="top">BOLD rs-fMRI</td><td valign="top">2.9 × 2.9 × 3.5</td><td valign="top">05:00</td><td valign="top">FOV 200 × 235 × 146 mm3; TR 2500 ms; 3 echos at TE 9.1, 25.3, and 41.4 ms ???</td></tr><tr><td valign="top">Qflow</td><td valign="top">1.2 × 1.2 × 2.0</td><td valign="top">00:19</td><td valign="top">FOV 150 × 103 mm2; TR 14 ms; TE 3.7 ms; flip angle 25°; Venc 100 cm/s</td></tr><tr><td valign="top">ASL</td><td valign="top">3.0 × 3.1 × 7.0</td><td valign="top">06:00</td><td valign="top">FOV 240 × 240 × 133 mm3; pCASL; label duration 1800 ms; postlabeling delay 1800 ms; 40 dynamics</td></tr><tr><td colspan="4" align="left" valign="top">Munich</td></tr><tr><td valign="top">T1-weighted GE</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">05:08</td><td valign="top">FOV 256 × 256 × 192 mm3; TR 2500 ms; TE 4.37 ms; TI 1100 ms; flip angle 7°</td></tr><tr><td valign="top">T2-weighted TSE</td><td valign="top">0.9 × 0.9 × 0.9</td><td valign="top">03:42</td><td valign="top">FOV 263 × 350 × 350 mm3; TR 3200 ms; TE 408 ms</td></tr><tr><td valign="top">T2*-weighted GE</td><td valign="top">0.9 × 0.9 × 2.0</td><td valign="top">05:56</td><td valign="top">FOV 230 × 160 × 187 mm3; TR 35 ms; TE 5–30 ms; flip angle 15°</td></tr><tr><td valign="top">SWI</td><td valign="top">0.6 × 0.6 × 3.0</td><td valign="top">04:02</td><td valign="top">FOV 240 × 156 × 195 mm3; TR 28 ms; TE 20 ms; flip angle 9°</td></tr><tr><td valign="top">FLAIR</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">06:27</td><td valign="top">FOV 250 × 250 × 176 mm3; TR 5000 ms; TE 398 ms; TI 1800 ms</td></tr><tr><td valign="top">Diffusion MRI</td><td valign="top">2.0 × 2.0 × 2.0</td><td valign="top">07:47</td><td valign="top">FOV 240 × 150 × 240 mm3; TR 3800 ms; TE 104.8 ms; b-values 0, 1000 and 2000 s/mm2; 90 diffusion directions (30 for b = 1000 s/mm2 and 60 for b = 2000 s/mm2)</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0005</table-id><table-label>Table 5</table-label><table-caption>7T brain MRI protocol in fixed order. CSO= Semioval centre; BG= Basal Ganglia; M1= first segment of the middle cerebral artery; BOLD= Blood oxygenation level-dependent; fMRI= functional magnetic resonance imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time. *Total scan time for a heart rate of 80 bpm.</table-caption><table-wrap-foot>aA fast version of the T1-weighted sequence was added multiple times to assess potential subject motion during the scan, particularly after repositioning for attaching the mask for the hypercapnic challenge.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0005" orientation="portrait"><label>Table 5</label><caption><p>7T brain MRI protocol in fixed order. CSO= Semioval centre; BG= Basal Ganglia; M1= first segment of the middle cerebral artery; BOLD= Blood oxygenation level-dependent; fMRI= functional magnetic resonance imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time. *Total scan time for a heart rate of 80 bpm.</p></caption><alt-text id="alt0007">Table 5:</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">MR sequence</th><th valign="top" colspan="1" rowspan="1">Acquired resolution mm<sup>3</sup></th><th valign="top" colspan="1" rowspan="1">Time min:s</th><th valign="top" colspan="1" rowspan="1">Parameters</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">T1-weighted</td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">01:59</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 190 mm<sup>3</sup>; TR 4.2 ms; TI 1297 ms; shot interval 3000 ms; flip angle 5°</td></tr><tr><td valign="top" colspan="1" rowspan="1">2D-Qflow CSO</td><td valign="top" colspan="1" rowspan="1">0.3 × 0.3 × 2.0</td><td valign="top" colspan="1" rowspan="1">03:24*</td><td valign="top" colspan="1" rowspan="1">FOV 230 × 230 mm<sup>2</sup>; reconstructed resolution 0.18 × 0.18 mm <xref rid="bib0002" ref-type="bibr">[2]</xref><sup>;</sup> TR 29 ms; TE 16 ms; Venc 4 cm/s</td></tr><tr><td valign="top" colspan="1" rowspan="1">T1-weighted<xref rid="tb5fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">00:47</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 190; TR 4.1 ms; TI 1253 ms; shot interval 3000; flip angle 5°</td></tr><tr><td valign="top" colspan="1" rowspan="1">2D-Qflow BG</td><td valign="top" colspan="1" rowspan="1">0.3 × 0.3 × 2.0</td><td valign="top" colspan="1" rowspan="1">03:47*</td><td valign="top" colspan="1" rowspan="1">FOV 170 × 170 mm<sup>2</sup>; reconstructed resolution 0.18 × 0.18 mm<sup>2;</sup>TR 28 ms; TE 15 ms; Venc 20 cm/s</td></tr><tr><td valign="top" colspan="1" rowspan="1">2D-Qflow M1</td><td valign="top" colspan="1" rowspan="1">0.5 × 0.5 × 3.0</td><td valign="top" colspan="1" rowspan="1">01:47*</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 200 mm<sup>2</sup>; TR 12 ms; TE 4.3 ms; Venc 100 cm/s</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2* whole brain</td><td valign="top" colspan="1" rowspan="1">0.6 × 0.6 × 0.6</td><td valign="top" colspan="1" rowspan="1">03:02</td><td valign="top" colspan="1" rowspan="1">FOV 239 × 191 × 100 mm<sup>3</sup>; TR 77 ms; TE 27 ms; flip angle 20°</td></tr><tr><td valign="top" colspan="1" rowspan="1">T2* visual cortex</td><td valign="top" colspan="1" rowspan="1">0.6 × 0.6 × 1.0</td><td valign="top" colspan="1" rowspan="1">02:21</td><td valign="top" colspan="1" rowspan="1">FOV 160 × 169 × 29 mm<sup>3</sup>; TR 1250 ms; TE 16 ms; flip angle 40°</td></tr><tr><td valign="top" colspan="1" rowspan="1">BOLD fMRI<break/>visual cortex<xref rid="tb5fn2" ref-type="table-fn">b</xref></td><td valign="top" colspan="1" rowspan="1">1.3 × 1.3 × 1.3</td><td valign="top" colspan="1" rowspan="1">10:05</td><td valign="top" colspan="1" rowspan="1">FOV 140 × 140 × 11 mm<sup>3</sup>; TR 880 ms; TE 25 ms</td></tr><tr><td valign="top" colspan="1" rowspan="1">T1-weighted<xref rid="tb5fn1" ref-type="table-fn">a</xref></td><td valign="top" colspan="1" rowspan="1">1.0 × 1.0 × 1.0</td><td valign="top" colspan="1" rowspan="1">00:47</td><td valign="top" colspan="1" rowspan="1">FOV 250 × 250 × 190 mm<sup>3</sup>; TR 4.1 ms; TI 1253 ms; shot interval 3000; flip angle 5°</td></tr><tr><td valign="top" colspan="1" rowspan="1">BOLD fMRI<break/>whole-brain<xref rid="tb5fn3" ref-type="table-fn">c</xref></td><td valign="top" colspan="1" rowspan="1">2.0 × 2.0 × 2.0</td><td valign="top" colspan="1" rowspan="1">10:00</td><td valign="top" colspan="1" rowspan="1">FOV 224 × 256 × 101 mm<sup>3</sup>; TR 3000 ms; TE 25 ms</td></tr></tbody></table><table-wrap-foot><fn id="tb5fn1"><label>a</label><p id="notep0001">A fast version of the T1-weighted sequence was added multiple times to assess potential subject motion during the scan, particularly after repositioning for attaching the mask for the hypercapnic challenge.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn2"><label>b</label><p id="notep0002">The participant is presented with a visual stimulus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tb5fn3"><label>c</label><p id="notep0003">The participant undergoes a hypercapnic challenge.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">7T brain MRI protocol in fixed order. CSO= Semioval centre; BG= Basal Ganglia; M1= first segment of the middle cerebral artery; BOLD= Blood oxygenation level-dependent; fMRI= functional magnetic resonance imaging; FOV= Field of view; TE= Echo Time; TI= Inversion Time; TR= Repetition Time. *Total scan time for a heart rate of 80 bpm.</div>Table 5:<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">MR sequence</th><th valign="top">Acquired resolution mm3</th><th valign="top">Time min:s</th><th valign="top">Parameters</th></tr></thead><tbody><tr><td valign="top">T1-weighted</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">01:59</td><td valign="top">FOV 250 × 250 × 190 mm3; TR 4.2 ms; TI 1297 ms; shot interval 3000 ms; flip angle 5°</td></tr><tr><td valign="top">2D-Qflow CSO</td><td valign="top">0.3 × 0.3 × 2.0</td><td valign="top">03:24*</td><td valign="top">FOV 230 × 230 mm2; reconstructed resolution 0.18 × 0.18 mm ???; TR 29 ms; TE 16 ms; Venc 4 cm/s</td></tr><tr><td valign="top">T1-weighted???</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">00:47</td><td valign="top">FOV 250 × 250 × 190; TR 4.1 ms; TI 1253 ms; shot interval 3000; flip angle 5°</td></tr><tr><td valign="top">2D-Qflow BG</td><td valign="top">0.3 × 0.3 × 2.0</td><td valign="top">03:47*</td><td valign="top">FOV 170 × 170 mm2; reconstructed resolution 0.18 × 0.18 mm2;TR 28 ms; TE 15 ms; Venc 20 cm/s</td></tr><tr><td valign="top">2D-Qflow M1</td><td valign="top">0.5 × 0.5 × 3.0</td><td valign="top">01:47*</td><td valign="top">FOV 250 × 200 mm2; TR 12 ms; TE 4.3 ms; Venc 100 cm/s</td></tr><tr><td valign="top">T2* whole brain</td><td valign="top">0.6 × 0.6 × 0.6</td><td valign="top">03:02</td><td valign="top">FOV 239 × 191 × 100 mm3; TR 77 ms; TE 27 ms; flip angle 20°</td></tr><tr><td valign="top">T2* visual cortex</td><td valign="top">0.6 × 0.6 × 1.0</td><td valign="top">02:21</td><td valign="top">FOV 160 × 169 × 29 mm3; TR 1250 ms; TE 16 ms; flip angle 40°</td></tr><tr><td valign="top">BOLD fMRIvisual cortex???</td><td valign="top">1.3 × 1.3 × 1.3</td><td valign="top">10:05</td><td valign="top">FOV 140 × 140 × 11 mm3; TR 880 ms; TE 25 ms</td></tr><tr><td valign="top">T1-weighted???</td><td valign="top">1.0 × 1.0 × 1.0</td><td valign="top">00:47</td><td valign="top">FOV 250 × 250 × 190 mm3; TR 4.1 ms; TI 1253 ms; shot interval 3000; flip angle 5°</td></tr><tr><td valign="top">BOLD fMRIwhole-brain???</td><td valign="top">2.0 × 2.0 × 2.0</td><td valign="top">10:00</td><td valign="top">FOV 224 × 256 × 101 mm3; TR 3000 ms; TE 25 ms</td></tr></tbody></table></div>aA fast version of the T1-weighted sequence was added multiple times to assess potential subject motion during the scan, particularly after repositioning for attaching the mask for the hypercapnic challenge.bThe participant is presented with a visual stimulus.cThe participant undergoes a hypercapnic challenge.</transformed-table></extracted-table></extracted-tables-set>